NKTX Nkarta, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $29.46M | $29.05M | $24.99M | $25.28M | $20.20M | $20.78M | $24.17M | $23.13M |
| SG&A expense | $6.31M | $14.08M | $5.89M | $5.68M | $7.09M | $6.41M | $12.39M | $7.80M |
| Operating income | -$35.78M | -$43.13M | -$30.88M | -$30.96M | -$27.29M | -$27.19M | -$36.56M | -$30.92M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.33M | -$40.37M | -$27.83M | -$27.41M | -$21.71M | -$22.98M | -$31.98M | -$25.93M |
| EBITDA | -$33.68M | -$40.43M | -$28.58M | -$28.66M | -$24.99M | -$24.89M | -$34.26M | -$28.62M |
| EPS (basic) | -0.45 | -0.54 | -0.37 | — | -0.29 | -0.31 | -0.43 | — |
| EPS (diluted) | -0.45 | -0.54 | -0.37 | — | -0.29 | -0.31 | -0.43 | — |
| Weighted avg. shares (diluted) | 74.64M | 74.49M | 74.26M | — | 74.02M | 73.98M | 73.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $48.35M | $24.96M | $27.36M | $39.63M | $60.11M | $53.41M | $52.60M | $27.87M |
| Short-term investments | $108.25M | $157.81M | $203.07M | $236.65M | $222.22M | $236.27M | $212.91M | $239.48M |
| Current assets | $162.55M | $188.04M | $235.88M | $282.51M | $289.27M | $296.57M | $271.55M | $273.34M |
| PP&E, net | $54.59M | $56.77M | $64.42M | $66.72M | $64.42M | $70.34M | $72.62M | $74.66M |
| Total assets | $308.46M | $337.64M | $372.07M | $404.21M | $427.24M | $448.31M | $470.61M | $501.20M |
| Current liabilities | $28.07M | $23.56M | $18.21M | $22.27M | $18.99M | $18.93M | $18.76M | $18.92M |
| Total liabilities | $92.71M | $89.91M | $86.21M | $91.88M | $89.34M | $90.64M | $91.80M | $93.23M |
| Shareholders' equity | $215.75M | $247.74M | $285.86M | $312.32M | $337.90M | $357.67M | $378.81M | $407.98M |
| Shares outstanding | — | — | — | 71.08M | — | — | — | 70.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.84M | -$24.22M | -$28.20M | -$21.65M | -$18.69M | -$18.75M | -$29.61M | -$24.75M |
| Capital expenditure | $1.25M | $183,000 | $413,000 | $560,000 | -$8,000 | $138,000 | $518,000 | $1.10M |
| Free cash flow | -$27.08M | -$24.41M | -$28.61M | -$22.21M | -$18.68M | -$18.89M | -$30.13M | -$25.85M |
| Investing cash flow | $49.09M | $21.15M | $15.91M | $1.10M | $25.39M | $19.49M | $54.34M | -$4.52M |
| Financing cash flow | $143,000 | $676,000 | $6,000 | $64,000 | $0 | $77,000 | $0 | $184,000 |
| Depreciation & amortization | $2.10M | $2.70M | $2.30M | $2.30M | $2.30M | $2.30M | $2.30M | $2.30M |
| Stock-based compensation | $1.76M | $1.86M | $1.90M | $1.90M | $1.77M | $2.05M | $2.83M | $3.89M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.